BIZURMI

Glaxo Group Limited

Application Filed: 2023-09-12

Trademark Application Details

Status

630

Live/Pending

NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER

Research	OneLook Acronym Finder
Serial Number	98175989
Mark Drawing Code	4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form
Attorney Name	Elizabeth K. Rucki
Attorney Docket Number	84262962

Timeline

2023-09-12	Application Filed
2023-09-15	Location: NEW APPLICATION PROCESSING
2023-09-15	Status: Live/Pending
2023-09-15	Transaction Date

Trademark Applicants & Owners

Owner:	Glaxo Group Limited
Entity Statement	private company limited by shares (prc)
Address	GSK Medicines Research Centre Gunnels Wood Road Stevenage GB SG12NY
Legal Entity Type
Legal Entity State	GB

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

ELIZABETH K. RUCKI
GSK
410 BLACKWELL STREET
LEGAL BRAND PROTECTION
DURHAM, NC 27701

Good, Services, and Codes

International Codes:	5
U.S. Codes:	005,006,018,044,046,051,052

Type Code	Type
GS0051	(Based on Intent to Use) Vaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders(Based on 44(d) Priority Application) Vaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders(Based on 44(e)) Vaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders

Type Code

Type

GS0051

(Based on Intent to Use) Vaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders(Based on 44(d) Priority Application) Vaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders(Based on 44(e)) Vaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders

Trademark Filing History

Description	Date	Event Coding
NEW APPLICATION ENTERED	2023-09-15	1 NWAP I:Incoming Correspondence
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED	2023-10-05	2 NWOS I:Incoming Correspondence
ASSIGNED TO EXAMINER	2024-03-26	3 DOCK D:Assigned to Examiner
APPROVED FOR PUB - PRINCIPAL REGISTER	2024-04-01	4 CNSA P:
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED	2024-04-17	5 NONP E:E-Mail
PUBLISHED FOR OPPOSITION	2024-05-07	6 PUBO A:Allowance for Publication
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED	2024-05-07	7 NPUB E:E-Mail

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.